ArticleIntractable & rare diseases research2026
Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis.
Article in Intractable & rare diseases research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports of cutaneous lymphomas (CL) following dupilumab administration are increasingly being documented, most frequently in patients with atopic dermatitis (AD). However, information regarding the association between CL and other biologic agents (nemolizumab, tralokinumab, or lebrikizumab) used for the treatment of AD is limited. To date, no large-scale pharmacovigilance study has systematically evaluated this issue in Japan. Therefore, we conducted a case investigation and disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database. Reports registered between April 2004 and August 2025 were analyzed. Both frequentist and Bayesian disproportionality analyses were performed using the reporting odds ratio (ROR) and information component (IC). In the primary analysis, including all reports in the JADER database, the ROR for dupilumab was 257.64 (95% confidence interval [CI], 164.50-404.39), and the IC was 4.52 (IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.